Scribe Therapeutics Inc. (NasdaqGM: SCTX)
Health Care · Biotechnology · US
$16.36
-3.71% today · -24.4% 1Y
Scribe Therapeutics Inc. (NasdaqGM: SCTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $309.82M and employs 89 people.
Over the last twelve months the share price has lost 24.4%, trading between 13.50 and 39.60.
Tweenvest scores Scribe Therapeutics Inc. across four factors: quality 32/100, value 79/100. Its strongest factor is value.
SCTX price history
Key figures
- Market cap
- $309.82M
- Revenue (TTM)
- $14.83M
- P/E
- -9.59
- EPS
- -13.13
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $39.60
- 52-week low
- $13.50
- Avg volume (3M)
- —
- Shares outstanding
- 18.94M
- Employees
- 89
- Next earnings
- —
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
- ISIN
- US8110331092
- Founded
- 2017
- Listed since
- Jul 24, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $320.09M | $10.99 | -1.87% |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $318.59M | $3.12 | -1.58% |
| Benitec Biopharma Inc.NasdaqCM: BNTC | $317.08M | $9.09 | -4.01% |
| OBI Pharma, Inc.TPEX: 4174 | $312.93M | NT$78.40 | +9.96% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $307.59M | $3.05 | -2.87% |
| Vector Science and Therapeutics Corp.TSXV: PAIN | $307.08M | CA$2.80 | +16.67% |
| Jiangsu Recbio Technology Co., Ltd.SEHK: 2179 | $306.59M | HK$3.90 | 0.00% |
| HJ Science Co., Ltd.SEHK: 6132 | $304.32M | HK$32.44 | -2.99% |